Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Awarepoint Announces Real-Time Location System (RTLS) Deployment To Moores Cancer Center
Awarepoint Corporation announced deployment of its Real-time Location System (RTLS) at the Rebecca and John Moores UCSD Cancer Center. This deployment adds a third UCSD Medical Center hospital to Awarepoint"s RTLS coverage, which currently includes the system"s Thornton and Hillcrest campuses. The Awarepoint enterprise RTLS installation has now been expanded to include nearly 1.5 million square feet with more than 2,000 assets under management, covering three hospitals across nearly 14 miles.
generic viagra online
Black Women More Likely To Have Vitamin D Deficiency, Bacterial Vaginosis, Study Finds
Black women are nearly three times as likely as white women to have a vitamin D deficiency, which is linked with an increased risk of the vaginal infection bacterial vaginosis, according to a study published in the June issue of the Journal of Nutrition, the New York Times reports. Black women likely have lower levels of vitamin D because the higher amount of pigment in their skin prevents the body from absorbing the vitamin.For the study, researchers led by Lisa Bodnar, an assistant professor of epidemiology at the University of Pittsburgh, examined 209 white pregnant women and 260 black pregnant women at a Pittsburgh clinic. More than half of the women had low levels of vitamin D, the study found. Women whose vitamin D levels were 50 nanomoles or less had a 26% increased risk of BV, while women whose vitamin levels were less than 20 nanomoles had a 65% increased risk of the infection. About 52% of black women had the infection, compared with 27% of white women, the study found (Bakalar, New York Times, 5/26). The study found that 93% of women with BV had low vitamin D levels and that BV prevalence decreased as vitamin levels increased.In addition, although black women were more likely to have BV, white women who had low levels of vitamin D were as likely to have the infection as black women. Poor diets and obesity also contributed to a vitamin deficiency. Bodnar noted that black women are less likely than white women to meet dietary recommendations for vitamin D. Bodnar recommended that women discuss their level of vitamin D with their physicians and that pregnant women take a prenatal vitamin, which typically includes vitamin D.According to the Pittsburgh Post-Gazette, Bodnar"s research team has received NIH funding to conduct a study of whether vitamin D deficiency in women increases the risk of poor birth outcomes and whether high infant mortality among blacks can be attributed to factors such as obesity (Templeton, Pittsburgh Post-Gazette, 5/23). Drugshop to buy zoloft online and other pills.
News of the day
Men Hit By 'Inexplicable' Greater Cancer Death Risk
Men are almost 40 per cent more likely than women to die from cancer, reveals a report published today (Monday) by the National Cancer Intelligence Network (NCIN) and Cancer Research UK together with the Men"s Health Forum to mark Men"s Health Week.
Oncology

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control And Reduces Weight

New Phase II data presented at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide. In the study, dose-dependent reductions in A1C - a measure of how well blood sugar is being controlled over time - with albiglutide 30 mg weekly, 50 mg biweekly, and 100 mg monthly were 0.9%, 0.8% and 0.9% respectively (pStudy design The primary objective of the study was to evaluate the dose response of albiglutide for safety and efficacy. The primary efficacy endpoint was change from baseline A1C at week 16 versus placebo across different doses within each schedule (weekly, biweekly, and monthly). The trial was a randomized, multi-center, double-blind, parallel-group study in 356 subjects with type 2 diabetes previously treated with diet and exercise or metformin (mean baseline A1C 8%). Patients received subcutaneous placebo, albiglutide weekly, (4, 15 or 30 mg), biweekly (15, 30 or 50 mg) or monthly (50 or 100 mg), or exenatide (open-label reference arm, in metformin-treated patients) over 16 weeks. About Albiglutide Albiglutide is an investigational biological, injectable form of human GLP-1 - a peptide that acts throughout the body to help maintain normal blood sugar levels and to control appetite. Normally, GLP-1 levels rise during a meal to help the body utilise and control the elevation in blood sugar levels. However, GLP-1 is rapidly degraded, resulting in its short duration of action. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced. Albiglutide is the only medication which fuses modified human GLP-1 to human albumin, a protein found in the blood plasma. It is designed to have an extended duration of action and allow for weekly or less-frequent injections. The Phase III programme for albiglutide began with five studies in early 2009 and is expected to last 2-3 years. The 30 mg weekly dose has been selected for the Phase III programme. GlaxoSmithKline one of the world"s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Syncria(R) is the registered trademark to be used in the United States. Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK"s operations are described under "Risk Factors" in the "Business Review" in the company"s Annual Report on Form 20-F for 2008. GlaxoSmithKline


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009